Toward the rational development of peptidomimetic analogs of the C-terminal endothelin hexapeptide: development of a theoretical model. 1998

M Macchia, and S Barontini, and F Ceccarelli, and C Galoppini, and L Giusti, and M Hamdan, and A Lucacchini, and A Martinelli, and E Menchini, and M R Mazzoni, and R P Revoltella, and F Romagnoli, and P Rovero
Dipartimento di Scienze Farmaceutiche, Università di Pisa, Italy.

In an early report on the structure-activity relationship of endothelin (ET) peptides, it was reported that the C-terminal hexapeptide ET(16-21), His-Leu-Asp-Ile-Ile-Trp, is the minimum ET fragment which maintains biological activity in some, but not all the tissues responding to ETs. Subsequently, other authors described a series of analogs of this peptide, in which the His 16 residue was replaced by non-natural amino acids, characterized by bulky aromatic side chains. Among them, two well-characterized non-selective ETA/ETB antagonists were PD 142893 and PD 145065; interest in these potent ET antagonists was, however, reduced by their peptidic structure which was likely to lead to undesirable properties such as poor bioavailability and short duration of action. On the basis of these premises, our previous studies led to the development of a peptidomimetic ligand of ET receptors (compound 3), based on the replacement of the His 16 residue of ET(16-21) with an (E)-N-(benzyloxy)iminoacyl moiety; compound 3 proved to possess a certain affinity for ET receptors, albeit lower than that shown by PD 142893 and PD 145065. We report here on ETA/ETB binding affinity of compounds 4-12, designed as a new series of ET(16-21) analogs. Compounds 4 and 5 were practically devoid of any affinity; derivatives 6-12 exhibited appreciable affinity indices for ETB receptors higher than that shown by 3, even if still lower than that obtained for PD 145065. This paper also describes the development of a pharmacophoric model able to explain the ET receptor binding properties of our hexapeptide analogs compared with those of PD 142893 and PD 145065 and IRL2500, recently reported as a potent ETB selective endothelin antagonist.

UI MeSH Term Description Entries
D008297 Male Males
D008956 Models, Chemical Theoretical representations that simulate the behavior or activity of chemical processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment. Chemical Models,Chemical Model,Model, Chemical
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D002531 Cerebellum The part of brain that lies behind the BRAIN STEM in the posterior base of skull (CRANIAL FOSSA, POSTERIOR). It is also known as the "little brain" with convolutions similar to those of CEREBRAL CORTEX, inner white matter, and deep cerebellar nuclei. Its function is to coordinate voluntary movements, maintain balance, and learn motor skills. Cerebella,Corpus Cerebelli,Parencephalon,Cerebellums,Parencephalons
D005260 Female Females
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014599 Uterus The hollow thick-walled muscular organ in the female PELVIS. It consists of the fundus which is the site of EMBRYO IMPLANTATION and FETAL DEVELOPMENT. Beyond the isthmus at the perineal end of fundus, is CERVIX UTERI (the neck) opening into VAGINA. Beyond the isthmi at the upper abdominal end of fundus, are the FALLOPIAN TUBES. Fundus Uteri,Uteri,Uterine Cornua,Uterine Fundus,Uterus Cornua,Womb,Cornua, Uterine,Fundus Uterus,Fundus, Uterine,Uteri, Fundus,Wombs

Related Publications

M Macchia, and S Barontini, and F Ceccarelli, and C Galoppini, and L Giusti, and M Hamdan, and A Lucacchini, and A Martinelli, and E Menchini, and M R Mazzoni, and R P Revoltella, and F Romagnoli, and P Rovero
August 1994, Pharmacology, biochemistry, and behavior,
M Macchia, and S Barontini, and F Ceccarelli, and C Galoppini, and L Giusti, and M Hamdan, and A Lucacchini, and A Martinelli, and E Menchini, and M R Mazzoni, and R P Revoltella, and F Romagnoli, and P Rovero
July 1989, European journal of pharmacology,
M Macchia, and S Barontini, and F Ceccarelli, and C Galoppini, and L Giusti, and M Hamdan, and A Lucacchini, and A Martinelli, and E Menchini, and M R Mazzoni, and R P Revoltella, and F Romagnoli, and P Rovero
September 1993, Journal of medicinal chemistry,
M Macchia, and S Barontini, and F Ceccarelli, and C Galoppini, and L Giusti, and M Hamdan, and A Lucacchini, and A Martinelli, and E Menchini, and M R Mazzoni, and R P Revoltella, and F Romagnoli, and P Rovero
August 1998, The Journal of pharmacy and pharmacology,
M Macchia, and S Barontini, and F Ceccarelli, and C Galoppini, and L Giusti, and M Hamdan, and A Lucacchini, and A Martinelli, and E Menchini, and M R Mazzoni, and R P Revoltella, and F Romagnoli, and P Rovero
May 1990, Neuropeptides,
M Macchia, and S Barontini, and F Ceccarelli, and C Galoppini, and L Giusti, and M Hamdan, and A Lucacchini, and A Martinelli, and E Menchini, and M R Mazzoni, and R P Revoltella, and F Romagnoli, and P Rovero
May 1991, The European respiratory journal,
M Macchia, and S Barontini, and F Ceccarelli, and C Galoppini, and L Giusti, and M Hamdan, and A Lucacchini, and A Martinelli, and E Menchini, and M R Mazzoni, and R P Revoltella, and F Romagnoli, and P Rovero
March 1992, Japanese journal of pharmacology,
M Macchia, and S Barontini, and F Ceccarelli, and C Galoppini, and L Giusti, and M Hamdan, and A Lucacchini, and A Martinelli, and E Menchini, and M R Mazzoni, and R P Revoltella, and F Romagnoli, and P Rovero
March 1983, International journal of peptide and protein research,
M Macchia, and S Barontini, and F Ceccarelli, and C Galoppini, and L Giusti, and M Hamdan, and A Lucacchini, and A Martinelli, and E Menchini, and M R Mazzoni, and R P Revoltella, and F Romagnoli, and P Rovero
September 1993, Bioorganic & medicinal chemistry,
M Macchia, and S Barontini, and F Ceccarelli, and C Galoppini, and L Giusti, and M Hamdan, and A Lucacchini, and A Martinelli, and E Menchini, and M R Mazzoni, and R P Revoltella, and F Romagnoli, and P Rovero
September 1990, British journal of pharmacology,
Copied contents to your clipboard!